NCT06701903 - Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | Biotech Hunter

Enrollment

570

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions

Generalized Anxiety Disorder

Interventions

DRUG

ITI-1284 10 mg

ITI-1284 10 mg tablet, taken once daily, sublingual administration.

DRUG

ITI-1284 20 mg

ITI-1284 20 mg tablet, taken once daily, sublingual administration.

DRUG

Placebo

Matching placebo tablet, taken once daily, sublingual administration

Trial Locations (15)

19063

NOT_YET_RECRUITING

Clinical Site, Media

30030

NOT_YET_RECRUITING

Clinical Site, Decatur

32607

NOT_YET_RECRUITING

Clinical Site, Gainesville

32803

NOT_YET_RECRUITING

Cinical Site, Orlando

33176

RECRUITING

Clinical Site, Miami

72211

NOT_YET_RECRUITING

Clinical Site, Little Rock

73116

RECRUITING

Clinical Site, Oklahoma City

75231

NOT_YET_RECRUITING

Clinical Site, Dallas

75243

NOT_YET_RECRUITING

Clinical Site, Dallas

90024

NOT_YET_RECRUITING

Clinical Site, Los Angeles

90230

NOT_YET_RECRUITING

Clinical Site, Culver City

91316

NOT_YET_RECRUITING

Clinical Site, Encino

92056

RECRUITING

Clinical Site, Oceanside

98007

NOT_YET_RECRUITING

Clinical Site, Bellevue

02131

NOT_YET_RECRUITING

Clinical Site, Boston